Since we also did not find any relation between smoking and JCV infection in a sufficiently representative cohort, we conclude that smoking habits seem not to contribute additional stratification potential for selection of a high-risk PML group in natalizumab-treated MS patients. This evidence concerns the gene PML and myeloid sarcoma.